Naglazyme Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to improved diagnosis of lysosomal storage disorders, expansion of rare disease awareness programs, regulatory approvals for orphan drugs, increased availability of specialized treatment centers, early clinical validation of enzyme replacement therapies.

The growth in the forecast period can be attributed to growing investments in rare disease research, rising demand for long-term therapeutic solutions, expansion of personalized medicine approaches, increased government support for orphan drugs, advancements in biologic manufacturing technologies. Major trends in the forecast period include increasing adoption of enzyme replacement therapies, growing focus on rare disease treatment accessibility, expansion of specialized infusion-based therapies, rising emphasis on long-term disease management solutions, enhanced focus on patient-centric treatment protocols.

The rising incidence of rare genetic disorders is expected to propel the growth of the Naglazyme market in the coming years. Rare genetic disorders are uncommon inherited conditions caused by gene mutations, affecting only a small segment of the population. The increasing occurrence of these disorders can be linked to genetic mutations, advancements in genetic testing, and population growth. Naglazyme, an enzyme replacement therapy, assists patients with rare genetic disorders such as mucopolysaccharidosis VI (MPS VI) by breaking down and reducing the buildup of glycosaminoglycans (GAGs), thereby enhancing mobility, respiratory function, and overall quality of life. For example, in October 2024, according to the Cystic Fibrosis Trust, a UK-based charity supporting people with cystic fibrosis, around 11,148 cystic fibrosis patients were registered in 2022, increasing to 11,318 in 2023, representing a 1.5% year-over-year rise in patient registrations. Therefore, the growing incidence of rare genetic disorders is driving the expansion of the Naglazyme market.

The increase in healthcare spending is expected to drive the growth of the Naglazyme market going forward. Healthcare spending refers to the total outlay on health services and products, including medical care, hospital services, preventive care, medications, research, infrastructure, and administrative costs, aimed at maintaining or improving the health and well-being of individuals and populations. Healthcare spending is influenced by an aging population, advancements in medical technology, rising prevalence of chronic diseases, and growing demand for healthcare services. Healthcare expenditure supports Naglazyme by providing the essential funding for the development, distribution, and accessibility of specialized treatments like enzyme replacement therapy, ensuring that patients with rare genetic disorders such as mucopolysaccharidosis VI (MPS VI) receive the critical care needed to enhance their quality of life. For example, in May 2024, according to the Office for National Statistics, a UK-based government department, healthcare spending in the UK increased by 5.6% between 2022 and 2023 compared with growth of 0.9% in 2022. The UK healthcare expenditure was approximately $317.63 billion (£292 billion) in 2023. Therefore, the rise in healthcare spending is fueling the growth of the Naglazyme market.

The increasing adoption of personalized medicine is expected to drive the growth of the naglazyme market in the coming years. Personalized medicine focuses on tailoring medical treatments based on an individual’s genetic profile, lifestyle, and environment to achieve more effective outcomes. The growing adoption of personalized medicine is fueled by factors such as advancements in genomic research, enhanced diagnostic tools, and the rising demand for more targeted and efficient therapies. Personalized medicine supports naglazyme by customizing treatment plans according to a patient’s genetic profile and specific disease characteristics, maximizing the effectiveness of enzyme replacement therapy for individuals with rare genetic disorders like mucopolysaccharidosis VI (MPS VI), and ensuring more precise and effective disease management. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six in 2022. Thus, the increasing adoption of personalized medicine is driving the growth of the naglazyme market.

Major companies operating in the naglazyme market are BioMarin Pharmaceutical Inc.

North America was the largest region in the naglazyme market in 2025. The regions covered in the naglazyme market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the naglazyme market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the naglazyme market by increasing costs associated with imported biologic manufacturing inputs, cold-chain logistics materials, specialized infusion equipment, and quality-control reagents. North America and Europe are most affected due to reliance on cross-border sourcing of biologics and pharmaceutical-grade enzymes, while Asia-Pacific faces higher import costs for branded orphan drugs. These tariffs contribute to elevated treatment costs and pressure on healthcare reimbursement systems. However, they are also encouraging localized biologics manufacturing, regional supply chain optimization, and strategic partnerships to improve long-term treatment availability.

The naglazyme market research report is one of a series of new reports that provides naglazyme market statistics, including naglazyme industry global market size, regional shares, competitors with a naglazyme market share, detailed naglazyme market segments, market trends and opportunities, and any further data you may need to thrive in the naglazyme industry. This naglazyme market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Naglazyme (galsulfase) is an enzyme replacement therapy designed to treat mucopolysaccharidosis VI (MPS VI), also called Maroteaux-Lamy syndrome. It functions by providing the enzyme that is missing or deficient, aiding in the reduction of glycosaminoglycans (GAGs) buildup and helping to relieve some symptoms of the condition. The therapy is given through intravenous infusion, usually under the guidance of a healthcare professional experienced in managing MPS disorders.

Naglazyme is primarily indicated for the treatment of Maroteaux-Lamy syndrome and other rare lysosomal storage disorders. Maroteaux-Lamy syndrome is an uncommon genetic condition resulting from a deficiency of the enzyme arylsulfatase B. The therapy is appropriate for both pediatric and adult patients and is made available through multiple distribution channels, including hospital pharmacies, specialty pharmacies, retail pharmacies, online pharmacies, as well as government and public health programs. These channels also serve various end users such as hospitals, specialty clinics, research institutions, and homecare settings.

The naglazyme market consists of sales of injectable solution and lyophilized powder. Values in this market are ‘factory gate’ values, which represent the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.